Navigation Links
eltrombopag in Medical News

Novel therapeutic approaches may improve patient outcomes in several platelet disorders

...l transfusions were the same in both arms. Oral eltrombopag for the Long-Term Treatment of Patients With Chron... multicenter, phase III study found that long-term eltrombopag therapy compared with placebo treatment significan...icroliters. They were randomized to receive either eltrombopag at a starting dose of 50 mg once daily (135 patien...

PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL

...ewed studies evaluating the safety and efficacy of eltrombopag in the short-term setting. Clinical data were presented and discussed that support eltrombopag increased platelet counts and reduced bleeding. ...ne Development Center at GSK. "An FDA approval for eltrombopag would represent an important development for these...

GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder

...s an increased risk of bruising and bleeding.(1,2) eltrombopag is an investigational, once-daily oral treatment t...it a Marketing Authorization Application (MAA) for eltrombopag in Europe in 2008. About the Data Submitted ...enna, Austria. At the end of the trial, 59% of eltrombopag treated patients on the 50mg dose and 16% of place...

Eltrombopag studied in Idiopathic Thrombocytopenic Purpura

...investigational oral platelet growth factor called eltrombopag successfully increased platelet counts and decreas...ind for ITP patients, the Phase 2 study found that eltrombopag doses of 50 and 75 mg daily elevated platelet coun... of adverse effects was similar in the placebo and eltrombopag treated groups. "These findings represent an im...

Drug May Help Reverse Clotting Deficiency

... eltrombopag might also aid patients with hepatitis liver disea... begin antiviral therapy for their condition after eltrombopag raised their platelet counts. "Eltrombopag is ...ly bleeding and bruising," Schwartz explained. eltrombopag is thought to stimulate megakaryocytes, the bone m...

GSK’s New Anticancer Drug A Huge Success In Drug trail

...y small, is likely to be transformed next year with the launch of Tykerb and other blockbuster drugs, such as the cervical cancer vaccine Cervarix and eltrombopag that is a blood-clotting agent in the treatment of breast cancer. They are also developing a lung cancer vaccine that would stop the disease from spre...
eltrombopag in Medical Technology

Novel Therapeutic Approaches May Transform Treatment and Improve Patient Outcomes in Several Platelet Disorders

...fusions were the same in both arms. Oral eltrombopag for the Long-Term Treatment of Patients With Chron... multicenter, phase III study found that long-term eltrombopag therapy compared with placebo treatment significan...icroliters. They were randomized to receive either eltrombopag at a starting dose of 50 mg once daily (135 patien...

GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP

...hKline. GSK plans to submit a Marketing Authorization Application (MAA) for eltrombopag in Europe in 2008. Important Safety Information BOXED WARNI... to therapy with PROMACTA. Cataracts were observed in toxicology studies of eltrombopag in rodents. Perform a baseline ocular examination prior to administration o...

FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder

... GSK plans to submit a Marketing Authorization Application (MAA) for eltrombopag in the treatment of chronic ITP in Europe in 2008; the proposed trade name ... to therapy with PROMACTA. Cataracts were observed in toxicology studies of eltrombopag in rodents. Perform a baseline ocular examination prior to administration o...

GSK Update on FDA Review of Promacta(R) (Eltrombopag)

...May 30, the Oncology Drugs Advisory Committee unanimously voted, 16-0, that eltrombopag demonstrated a favorable risk-benefit profile for the short-term treatment ...pivotal studies, the most common adverse events observed in patients taking eltrombopag were headache, common cold, and nausea. About GlaxoSmithKline GlaxoSmit...

FDA Grants Priority Review for PROMACTA(R) (eltrombopag)

...it a Marketing Authorization Application (MAA) for eltrombopag in the treatment of chronic ITP in Europe in 2008 ...se are rare.(1) About PROMACTA (eltrombopag) eltrombopag is an oral, non-peptide thrombopoietin receptor ag...ne marrow cells that give rise to blood platelets. eltrombopag was discovered as a result of research collaborati...

Long-Term Safety and Efficacy Data on Promacta(TM) (Eltrombopag) Presented at American Society of Hematology Annual Meeting

...iries: Frank Murdolo 215-751-7002 Tom Curry 215-751-5419 REFERENCES (1) Bussel, JB., Cheng, G., et al. Long-term safety and efficacy of oral eltrombopag for the treatment of subjects with idiopathic thrombocytopenic purpura (ITP): preliminary data from the EXTEND study. Blood. 2007; 110 (11). Published...

Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP

...189 patients across 135 centers in 26 countries. REPEAT (Repeat ExPosure to eltrombopag in Adults with Idiopathic Thrombocytopenic Purpura) will involve 50 patient...51 5419 REFERENCES (1) Bussel, J., Provan A., Shamsi T et al. eltrombopag Raises Platelet Count and Reduces Bleeding compared with Placebo ...
eltrombopag in Biological News

Lancet study supports new, highly effective treatment for blood disorder

...ed late 2007 in the New England Journal of Medicine. This trial showed that eltrombopag was effective in raising platelet counts and lowering bleeding in adult sub...cts. Ongoing and future studies will evaluate the safety and efficacy of eltrombopag as a long-term treatment for ITP, and its efficacy and safety in population...

Eltrombopag effective for hepatitis C patients with low blood-platelet counts

...the door to effective treatment. "In this study, eltrombopag increased platelet counts in a dose-dependent mann...common reason for a liver transplant. With other eltrombopag findings, NewYork-Presbyterian/Weill Cornell's Dr.... GlaxoSmithKline, which is developing eltrombopag. eltrombopag (marketed as Promacta in the U.S. and Revolade in ...
Other Tags
(Date:6/3/2015)... BC (PRWEB) June 03, 2015 Vancouver ... announced that the firm will now handle personal injury ... Greater Vancouver on the rise, more and more people ... year bus accidents cause needless suffering, serious injury and ... a result of a bus accident in BC you ...
(Date:6/3/2015)... June 03, 2015 Array Health ... technology, has announced that CEO Jonathan Rickert will present ... on June 4, 2015. The session will address ... are disrupting traditional business models in health care, and ... , WHAT: Digital Transformation and the Health Care ...
(Date:6/3/2015)... 2015 A group of nine authors ... a Global Inspire Award at DIA’s upcoming Annual Meeting. ... volunteers for their leadership, level of excellence, and commitment ... The recipients of the Author(s) of the Year Award, ... article has made a significant impact in advancing medical ...
(Date:6/3/2015)... 2015 Z-Medica®, LLC, a leading developer ... has been designated as National Safety Month by the ... Police Department for its commitment to public safety. ... Individual First Aid Kits (IFAK) over 100 times in ... stabbings or traffic accidents. Each kit is equipped with ...
(Date:6/3/2015)... NC (PRWEB) June 03, 2015 Researchers ... two biomarkers for mesothelioma and say the tried-and-true marker ... just posted an article on the research. Click ... the University’s National Center for Asbestos Related Diseases say, ... positive results, it is still preferable to fibulin-3 for ...
Breaking Medicine News(10 mins):Health News:Jiwa Law Corporation Now Handles Personal Injury Claims Involving Bus Accidents 2Health News:Array Health’s CEO to Present at America’s Health Insurance Plans Institute 2015 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 4Health News:Z-Medica Commends Tucson Police Department for Trauma Kit Utilization 2Health News:Analysis Reveals Gold Standard Mesothelioma Biomarker Still the Best, According to Surviving Mesothelioma 2
(Date:5/29/2015)... 28, 2015 Research and Markets ( ... "Facial Recognition Market by Solution, by Software, ... to 2020" report to their offering. ... recognition technology become more efficient and cost effective. ... and investment from the commercial sector. The development ...
(Date:5/22/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... promotional pricing and making the Wocket generally available for $229 ... Head of Marketing said, "We,ve extended the opportunity to take ... May. To get your wocket at this special price, submit ... on June 1, you,ll receive a unique code that gives ...
(Date:5/20/2015)... , May 20, 2015 NXT-ID, Inc. ... that its wholly owned subsidiary, 3D-ID LLC, a company ... Team Battelle for the biometrics technology portion of the ... Contract from the Department of the Army. ... products developed for government, law enforcement and security agencies. ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
Other Contents